My Treatment Approach: HER2+ Breast Cancer - Episode 9

Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses

June 17, 2024

Tiffany A. Traina, MD, VK Gadi, MD, PhD, Heather McArthur, MD, MPH

Key opinion leaders revisit the HER2CLIMB trial, providing an in-depth analysis of the latest updates and their implications for the management of HER2-positive metastatic breast cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

EP. 2: Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

EP. 3: First-Line HER2+ Metastatic Breast Cancer Trials in Focus

EP. 4: Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd

EP. 5: Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

EP. 6: Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer

EP. 7: TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting

EP. 8: Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

Now Viewing

EP. 9: Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses

EP. 10: Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches

EP. 11: Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions